Summary of minutes of EUCAST Steering Committee Meeting
Basel, Switzerland, 10-11 November 2014

Attending
Dr Derek F.J. Brown                       DB  Scientific Secretary  United Kingdom
Dr Rafael Cantón                           RC  Chairperson            Spain
Prof Luc Dubreuil                         LD  CA-SFM                   France
Dr Christian Giske                         CG  SRGA                     Sweden
Prof Gunnar Kahlmeter                      GK  Clinical Data Co-ordinator  Sweden
Prof Alasdair P. MacGowan                 AM  BSAC                     United Kingdom
Prof Johan W. Mouton                      JM  CRG                       The Netherlands
Prof Sören Gatermann                      SG  EUCAST General Committee  Germany
Dr Martin Steinbakk                      MS  NWGA                     Norway
Dr Iztok Štrumbelj                        IS  EUCAST General Committee  Slovenia
Prof Jan Verhagen                         JV  EUCAST General Committee  Belgium

Visiting GC members:
Prof Ron Jones                            RJ  EUCAST General Committee  USA
Dr Radu Botgros                           RB  EMA                       UK

Present for item 21 and 23:
Company representatives

1  Chairman’s welcome
   Prof Ron Jones (USA) was present as General Committee visiting member.

2  Minutes of meeting of 15-16 September 2014
   Accepted with minor modifications.

3  Matters arising from minutes of 15-16 September 2014 (items not covered by agenda)
   None.

4  New agents
   Antimycobacterial breakpoints have been included in version 5.0 of the breakpoint tables.
   Breakpoint issues related to new oxazolidinone and glycopeptide agents were discussed.

5  EUCAST rationale documents
   Updating the format of old rationale documents will continue as time allows. The ceftaroline
document has been released and the ceftobiprole document is close to completion. Other
outstanding documents are in various stages of development.

6  Subcommittees
   6.1 Antifungal susceptibility testing: No new information.
   Whole genome sequencing (WGS): A subcommittee will be set up to outline the current position and
problems for prediction of antimicrobial susceptibility from WGS results.

7  Breakpoint issues
   7.1 Breakpoint tables version 5.0 were reviewed and the preliminary version will be released early in
November 2014.
   Neisseria meningitidis: Revised breakpoints of S ≤ 0.03, R >0.03 mg/L for ciprofloxacin, without an
intermediate category, are included in breakpoint tables version 5.0.
   Breakpoints for N. gonorrhoeae: WHO QC strains are to be included in QC tables on the website.
   Acinetobacter spp.: More sulbactam MIC distributions are needed before breakpoints can be set.
   Colistin breakpoints: A final report is currently being written by the joint EUCAST-CLSI group.
   Review of carbapenem breakpoints: In progress.
   Dissociated resistance to clindamycin: Changes in reporting and comments have been included in
breakpoint tables, version 5.0.
Expert rules review: In progress.

Guidelines for manufacturers on data required for new antimycobacterial agents: A workshop with the ESGMYC will follow this meeting.

Ampicillin/amoxicillin intermediate in *S. pneumoniae*: Agreed changes to the comment have been included in breakpoint tables, version 5.0.

Daptomycin breakpoints for enterococci: Clinical breakpoints cannot be justified on PK/PD grounds. It was agreed to leave breakpoints as IE and to link this to a guidance note.

Tigecycline breakpoints for Enterobacteriaceae: There will be a wide consultation on modified breakpoint proposals.

Nitrooxine and spiramycin breakpoints: There will be wide consultations on breakpoint proposals.

Temocillin breakpoints: New PK/PD data are to be produced before setting breakpoints.

Teicoplanin breakpoints for coagulase-negative staphylococci: Wide distributions for some species probably include both wild type and isolates with reduced susceptibility. There is no evidence to support changes to breakpoints at present.

Agents without breakpoints: A list indicating whether breakpoints are available, and if not the reason for the omission is being prepared.

Veterinary breakpoints: VETCAST is being re-established as a EUCAST subcommittee.

Review of fluoroquinolone breakpoints: Breakpoint committees are currently being consulted on proposals.

Aztreonam breakpoints for *Pseudomonas* spp: There will be wide consultation on a proposal to change the breakpoints to ensure that the wild type are in the intermediate category.

Organisms without EUCAST breakpoints: Work continues on several groups of organisms.

EUCAST methods

Disk diffusion development work underway or completed includes disk diffusion and QC studies on new agents, evaluation of differences in disk potency between manufacturers, interpretive criteria for *Aerococcus* spp., zone diameter ECOFFs for *Salmonella* and *Campylobacter* spp., a pilot study on methods for *Kingella kingae* and fosfomycin disk diffusion susceptibility testing.

Routine QC for clavulanic acid activity will be included in the table of routine QC strains rather than the table of additional strains.

It was noted that a disk diffusion screen for carbapenemase activity is included in the EUCAST document “Detection of resistance mechanisms for clinical and/or public health importance”, which is on the EUCAST website.

Available panels for the broth microdilution MIC determination service at the EUCAST Development Laboratory are listed on the EUCAST website.

Implementation of EUCAST breakpoints: No new information.

EUCAST websites

A separate section with all open consultations and responses is being prepared.

Some website usage statistics will be included on the website.

Documents on EUCAST Network and Development Laboratories are now on the website.

Publications and presentations: A paper on uptake of EUCAST breakpoints for the
| 13 | **NACs** The German NAC replacing the disbanded DIN committee will have a “permanent” representative on the Steering Committee. |
| 14 | **EUCAST SOPs** The updated SOP on EUCAST committees (SOP 4.1) and the SOP on Development of QC criteria and zone diameter breakpoints (SOP 9.0) are on the website. |
| 15 | **ESCMID** The Postgraduate Educational Course, Linz, Tuesday 16 – Friday 19 September 2014 was successful and was highly rated by the participants. |
| 16 | **EMA** A revised EMA-EUCAST SOP is expected soon. |
| 17 | **ECDC** A new call for tender for EUCAST activity is yet to be released. |
| 18 | **CLSI** RC has been invited to be a CLSI advisor due his current position as EUCAST Chairman. |
| 19 | **Recommendations on generation and reporting of statistics on bacterial resistance** It was agreed that this is an action area for ESGARS rather than EUCAST. |
| 20-22 | **Cephalosporin-β-lactamase inhibitor combination** The company presented the agent to EUCAST and there was discussion of breakpoints. |
| 23 | **New cephalosporin** The company gave a preliminary presentation of the agent to EUCAST. Aspects of susceptibility testing and breakpoint setting were discussed. |
| 24 | **Any other business** None. |
| 25 | **Next meetings**  
16-17 February 2015, Leuven, Belgium.  
28-29 April 2015, Copenhagen, Denmark (immediately following ECCMID).  
13-14 July 2015, London, UK  
7-8 September 2015, Stockholm, Sweden  
9-10 November, 2015, venue to be decided  
8-9 February 2016, venue to be decided |

Ratified summary of minutes of meeting 10-11 November 2014. Prepared by DB, RC and GK